Carregant...

Bortezomib in the rapid reduction of high sustained antibody titers in disorders treated with therapeutic protein: lessons learned from Pompe disease

PURPOSE: High sustained antibody titers complicate many disorders treated with a therapeutic protein, including those treated with enzyme replacement therapy, such as Pompe disease. Although enzyme replacement therapy with alglucosidase alfa (Myozyme) in Pompe disease has improved the prognosis of t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Banugaria, Suhrad G., Prater, Sean N., McGann, Judeth K., Feldman, Jonathan D., Tannenbaum, Jesse A., Bailey, Carrie, Gera, Renuka, Conway, Robert L., Viskochil, David, Kobori, Joyce A., Rosenberg, Amy S., Kishnani, Priya S.
Format: Artigo
Idioma:Inglês
Publicat: 2012
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3744338/
https://ncbi.nlm.nih.gov/pubmed/23060045
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/gim.2012.110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!